aeid,assay_component_endpoint_name,tissue,cell_format,cell_short_name,assay_source_desc,assay_component_desc,assay_component_target_desc,assay_component_endpoint_desc
314,BSK_SAg_PBMCCytotoxicity,vascular,primary cell co-culture,umbilical vein endothelium and peripheral blood mononuclear cells,Bioseek is a division of DiscoveRx Corporation and developed the BioMAP system providing uniquely informative biological activity profiles in complex human primary cell systems.,BSK_SAg_PBMCCytotoxicity is an assay component measured in the BSK_SAg assay. It measures Alamar blue related to cell death using Alamar Blue Reduction technology.,Changes to fluorescence intensity signals produced from an enzymatic reaction involving the key substrate [Alamar blue] are correlated to the viability of the cells in the system.,"Data from the assay component BSK_SAg_PBMCCytotoxicity was analyzed into 1 assay endpoint. This assay endpoint, BSK_SAg_PBMCCytotoxicity, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, gain or loss-of-signal activity can be used to understand changes in the viability. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity."
763,TOX21_AR_BLA_Antagonist_viability,kidney,cell line,HEK293T,"Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.",TOX21_AR_BLA_Antagonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.,Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.,"TOX21_AR_BLA_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity."
766,TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881_viability,breast,cell line,MDA-kb2,"Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.",TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.,Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.,"TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity."
768,TOX21_Aromatase_Inhibition_viability,breast,cell line,MCF7,"Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.",TOX21_Aromatase_Inhibition_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.,Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.,"TOX21_Aromatase_Inhibition_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity."
782,TOX21_ELG1_LUC_Agonist_viability,kidney,cell line,HEK293T,"Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.",TOX21_ELG1_LUC_Agonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.,Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.,"TOX21_ELG1_LUC_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity."
795,TOX21_GR_BLA_Antagonist_viability,cervix,cell line,HeLa,"Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.",TOX21_GR_BLA_Antagonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.,Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.,"TOX21_GR_BLA_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity."
799,TOX21_MMP_viability,liver,cell line,HepG2,"Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.",TOX21_MMP_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.,Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.,"TOX21_MMP_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity."
807,TOX21_AhR_LUC_Agonist_viability,liver,cell line,HepG2,"Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.",TOX21_AhR_LUC_Agonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.,Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.,"TOX21_AhR_LUC_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity."
1121,TOX21_FXR_BLA_Antagonist_viability,kidney,cell line,HEK293T,"Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.",TOX21_FXR_BLA_Antagonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.,Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.,"TOX21_FXR_BLA_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity."
1126,TOX21_PPARd_BLA_Antagonist_viability,kidney,cell line,HEK293T,"Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.",TOX21_PPARd_BLA_Antagonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.,Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.,"TOX21_PPARd_BLA_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity."
1128,TOX21_PPARg_BLA_Antagonist_viability,kidney,cell line,HEK293,"Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.",TOX21_PPARg_BLA_Antagonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.,Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.,"TOX21_PPARg_BLA_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity."
1133,TOX21_VDR_BLA_Antagonist_viability,kidney,cell line,HEK293T,"Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.","TOX21_VDR_BLA_Antagonist_viability is one of 2 assay component(s) measured or calculated from the TOX21_VDR_BLA_Antagonist assay. It is designed to make measurements of ATP content, a form of viability reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.",Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.,"TOX21_VDR_BLA_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity."
1185,TOX21_ARE_BLA_agonist_viability,liver,cell line,HepG2,"Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.",TOX21_ARE_BLA_Agonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.,Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.,"TOX21_ARE_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity."
1186,TOX21_HSE_BLA_agonist_viability,cervix,cell line,HeLa,"Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.",TOX21_HSE_BLA_Agonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.,Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.,"TOX21_HSE_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity."
1187,TOX21_p53_BLA_p1_viability,intestinal,cell line,HCT116,"Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.",TOX21_p53_BLA_p1_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.,Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.,"TOX21_p53_BLA_p1_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity."
1188,TOX21_FXR_BLA_agonist_viability,kidney,cell line,HEK293T,"Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.",TOX21_FXR_BLA_Agonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.,Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.,"TOX21_FXR_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity."
1195,TOX21_PPARd_BLA_Agonist_viability,kidney,cell line,HEK293T,"Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.",TOX21_PPARd_BLA_Agonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.,Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.,"TOX21_PPARd_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity."
1318,TOX21_p53_BLA_p2_viability,intestinal,cell line,HCT116,"Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.",TOX21_p53_BLA_p2_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.,Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.,"TOX21_p53_BLA_p2_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity."
1322,TOX21_p53_BLA_p3_viability,intestinal,cell line,HCT116,"Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.",TOX21_p53_BLA_p3_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.,Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.,"TOX21_p53_BLA_p3_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity."
1326,TOX21_p53_BLA_p4_viability,intestinal,cell line,HCT116,"Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.",TOX21_p53_BLA_p4_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.,Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.,"TOX21_p53_BLA_p4_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity."
1330,TOX21_p53_BLA_p5_viability,intestinal,cell line,HCT116,"Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.",TOX21_p53_BLA_p5_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.,Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.,"TOX21_p53_BLA_p5_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity."
1331,TOX21_VDR_BLA_Agonist_viability,kidney,cell line,HEK293T,"Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.","TOX21_VDR_BLA_Agonist_viability is one of 2 assay component(s) measured or calculated from the TOX21_VDR_BLA_Agonist assay. It is designed to make measurements of ATP content, a form of viability reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.",Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.,"TOX21_VDR_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity."
1343,TOX21_ESRE_BLA_viability,cervix,cell line,HeLa,"Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.",TOX21_ESRE_BLA_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.,Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.,"TOX21_ESRE_BLA_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity."
1347,TOX21_NFkB_BLA_agonist_viability,cervix,cell line,ME-180,"Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.",TOX21_NFkB_BLA_Agonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.,Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.,"TOX21_NFkB_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity."
1509,CCTE_Simmons_CellTiterGLO_HEK293T,kidney,cell line,HEK293T,"The EPA Center for Computational Toxicology and Exposure labs focus on developing and implementing in vitro methods to identify potential environmental toxicants. Principal investigators include Steve Simmons, Joshua Harrill, and Chad Deisenroth.","CCTE_Simmons_CellTiterGLO_HEK293T is the assay component measured from the CCTE_Simmons_CellTiterGLO_HEK293T assay. It is designed to make measurements of ATP content, a form of viability reporter, as detected with bioluminescence signals by Luciferase-coupled ATP quantitation technology. This is a secondary cytotoxicity assay to CCTE_Simmons_AUR_TPO to estimate a cellular tolerance limit.",Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo Fluor] and the target cofactor [ATP] are correlated to the viability of the system.,"Data from the assay component CCTE_Simmons_CellTiterGLO_HEK293T was analyzed at the endpoint, CCTE_Simmons_CellTiterGLO_HEK293T, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, measures of ATP content for loss-of-signal activity can be used to understand the viability. This assay was run in parallel with aeid 1508 as a means of indicating the range of chemical cytotoxicity or reactivity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity."
1817,TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881_viability,breast,cell line,MDA-kb2,"Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.",TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.,Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.,"TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity."
1821,TOX21_RXR_BLA_Agonist_viability,kidney,cell line,HEK293T,"Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.",TOX21_RXR_BLA_Agonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.,Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.,"TOX21_RXR_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity."
1823,TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide_viability,breast,cell line,MDA-kb2,"Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.",TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.,Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.,"TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity."
1847,TOX21_AP1_BLA_Agonist_viability,cervix,cell line,ME-180,"Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.",TOX21_AP1_BLA_Agonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.,Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.,"TOX21_AP1_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle target family, where the subfamily is cytotoxicity."
2048,TOX21_CAR_Agonist_viability,liver,cell line,HepG2,"Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.",TOX21_CAR_Agonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.,Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.,"TOX21_CAR_Agonist_viabillity used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity."
2050,TOX21_CAR_Antagonist_viability,liver,cell line,HepG2,"Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.",TOX21_CAR_Antagonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.,Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.,"TOX21_CAR_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity."
2059,TOX21_ERR_viability,kidney,cell line,ERR-HEK293T,"Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.",TOX21_ERR_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.,Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.,"TOX21_ERR_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity."
2062,TOX21_HDAC_Inhibition_viability,colon,cell line,HCT116,"Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.",TOX21_HDAC_Inhibition_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.,Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.,"TOX21_HDAC_Inhibition_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity."
2066,TOX21_HRE_BLA_Agonist_viability,cervix,cell line,ME-180,"Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.",TOX21_HRE_BLA_Agonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.,Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.,"TOX21_HRE_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity."
2072,TOX21_PGC_ERR_viability,kidney,cell line,PGC/ERR HEK293T,"Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.",TOX21_PGC_ERR_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.,Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.,"TOX21_PGC_ERR_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity."
2075,TOX21_RT_HEK293_FLO_08hr_viability,kidney,cell line,HEK293,"Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.",TOX21_RT_HEK293_FLO_08hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEK293_FLO_00hr_viability. It is designed to make measurements of dead cells as detected with biofluorescent emission of fluorescent dye bound to dead cell DNA at 8 hr after exposure,TOX21_RT_HEK293_FLO_08hr_viability was designed to measure changes to biofluorescent signals produced from the key cyanine dye [CellTox Green] binding to dead cell DNA. Increases are indicative of decreased  viable cells present in the culture,"TOX21_RT_HEK293_FLO_08hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability"
2078,TOX21_RT_HEK293_FLO_24hr_viability,kidney,cell line,HEK293,"Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.",TOX21_RT_HEK293_FLO_24hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEK293_FLO_00hr_viability. It is designed to make measurements of dead cells as detected with biofluorescent emission of fluorescent dye bound to dead cell DNA at 24 hr after exposure,TOX21_RT_HEK293_FLO_24hr_viability was designed to measure changes to biofluorescent signals produced from the key cyanine dye [CellTox Green] binding to dead cell DNA. Increases are indicative of decreased  viable cells present in the culture,"TOX21_RT_HEK293_FLO_24hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability"
2080,TOX21_RT_HEK293_FLO_32hr_viability,kidney,cell line,HEK293,"Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.",TOX21_RT_HEK293_FLO_32hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEK293_FLO_00hr_viability. It is designed to make measurements of dead cells as detected with biofluorescent emission of fluorescent dye bound to dead cell DNA at 32 hr after exposure,TOX21_RT_HEK293_FLO_32hr_viability was designed to measure changes to biofluorescent signals produced from the key cyanine dye [CellTox Green] binding to dead cell DNA. Increases are indicative of decreased  viable cells present in the culture,"TOX21_RT_HEK293_FLO_32hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability"
2082,TOX21_RT_HEK293_FLO_40hr_viability,kidney,cell line,HEK293,"Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.",TOX21_RT_HEK293_FLO_40hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEK293_FLO_00hr_viability. It is designed to make measurements of dead cells as detected with biofluorescent emission of fluorescent dye bound to dead cell DNA at 40 hr after exposure,TOX21_RT_HEK293_FLO_40hr_viability was designed to measure changes to biofluorescent signals produced from the key cyanine dye [CellTox Green] binding to dead cell DNA. Increases are indicative of decreased  viable cells present in the culture,"TOX21_RT_HEK293_FLO_40hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability"
2086,TOX21_RT_HEK293_GLO_08hr_viability,kidney,cell line,HEK293,"Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.",TOX21_RT_HEK293_GLO_08hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEK293_GLO_00hr_viability assay. It is designed to make measurements of viable cells as detected with bioluminescence signal generated by NanoLuc luciferase catalysis of a profurimazine substrate which require intracellular reduction of the substrate in a viable cell.,TOX21_RT_HEK293_GLO_08hr_viability was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [Profurimazine]. Changes are indicative of changes in the number of viable cells which are required for reduction of Profurimazine to a form that can be used by NanoLuc luciferase added as a detection reagent.,"TOX21_RT_HEK293_GLO_08hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability"
2088,TOX21_RT_HEK293_GLO_16hr_viability,kidney,cell line,HEK293,"Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.",TOX21_RT_HEK293_GLO_16hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEK293_GLO_00hr_viability assay. It is designed to make measurements of viable cells as detected with bioluminescence signal generated by NanoLuc luciferase catalysis of a profurimazine substrate which require intracellular reduction of the substrate in a viable cell.,TOX21_RT_HEK293_GLO_16hr_viability was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [Profurimazine]. Changes are indicative of changes in the number of viable cells which are required for reduction of Profurimazine to a form that can be used by NanoLuc luciferase added as a detection reagent.,"TOX21_RT_HEK293_GLO_16hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability"
2089,TOX21_RT_HEK293_GLO_24hr_viability,kidney,cell line,HEK293,"Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.",TOX21_RT_HEK293_GLO_24hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEK293_GLO_00hr_viability assay. It is designed to make measurements of viable cells as detected with bioluminescence signal generated by NanoLuc luciferase catalysis of a profurimazine substrate which require intracellular reduction of the substrate in a viable cell.,TOX21_RT_HEK293_GLO_24hr_viability was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [Profurimazine]. Changes are indicative of changes in the number of viable cells which are required for reduction of Profurimazine to a form that can be used by NanoLuc luciferase added as a detection reagent.,"TOX21_RT_HEK293_GLO_24hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability"
2091,TOX21_RT_HEK293_GLO_32hr_viability,kidney,cell line,HEK293,"Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.",TOX21_RT_HEK293_GLO_32hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEK293_GLO_00hr_viability assay. It is designed to make measurements of viable cells as detected with bioluminescence signal generated by NanoLuc luciferase catalysis of a profurimazine substrate which require intracellular reduction of the substrate in a viable cell.,TOX21_RT_HEK293_GLO_32hr_viability was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [Profurimazine]. Changes are indicative of changes in the number of viable cells which are required for reduction of Profurimazine to a form that can be used by NanoLuc luciferase added as a detection reagent.,"TOX21_RT_HEK293_GLO_32hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability"
2093,TOX21_RT_HEK293_GLO_40hr_viability,kidney,cell line,HEK293,"Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.",TOX21_RT_HEK293_GLO_40hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEK293_GLO_00hr_viability assay. It is designed to make measurements of viable cells as detected with bioluminescence signal generated by NanoLuc luciferase catalysis of a profurimazine substrate which require intracellular reduction of the substrate in a viable cell.,TOX21_RT_HEK293_GLO_40hr_viability was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [Profurimazine]. Changes are indicative of changes in the number of viable cells which are required for reduction of Profurimazine to a form that can be used by NanoLuc luciferase added as a detection reagent.,"TOX21_RT_HEK293_GLO_40hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability"
2095,TOX21_RT_HEPG2_FLO_08hr_viability,liver,cell line,HepG2,"Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.",TOX21_RT_HepG2_FLO_08hr_viability is one of one assay component(s) measured or calculated from theTOX21_RT_HepG2_FLO_00hr_viability. It is designed to make measurements of dead cells as detected with biofluorescent emission of fluorescent dye bound to dead cell DNA at 8 hr after exposure,TOX21_RT_HepG2_FLO_08hr_viability was designed to measure changes to biofluorescent signals produced from the key cyanine dye [CellTox Green] binding to dead cell DNA. Increases are indicative of decreased  viable cells present in the culture,"TOX21_RT_HEPG2_FLO_08hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability"
2096,TOX21_RT_HEPG2_FLO_16hr_viability,liver,cell line,HepG2,"Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.",TOX21_RT_HepG2_FLO_16hr_viability is one of one assay component(s) measured or calculated from theTOX21_RT_HepG2_FLO_00hr_viability. It is designed to make measurements of dead cells as detected with biofluorescent emission of fluorescent dye bound to dead cell DNA at 16 hr after exposure,TOX21_RT_HepG2_FLO_16hr_viability was designed to measure changes to biofluorescent signals produced from the key cyanine dye [CellTox Green] binding to dead cell DNA. Increases are indicative of decreased  viable cells present in the culture,"TOX21_RT_HEPG2_FLO_16hr_ctrl_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability"
2097,TOX21_RT_HEPG2_FLO_24hr_viability,liver,cell line,HepG2,"Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.",TOX21_RT_HepG2_FLO_24hr_viability is one of one assay component(s) measured or calculated from theTOX21_RT_HepG2_FLO_00hr_viability. It is designed to make measurements of dead cells as detected with biofluorescent emission of fluorescent dye bound to dead cell DNA at 24 hr after exposure,TOX21_RT_HepG2_FLO_24hr_viability was designed to measure changes to biofluorescent signals produced from the key cyanine dye [CellTox Green] binding to dead cell DNA. Increases are indicative of decreased  viable cells present in the culture,"TOX21_RT_HEPG2_FLO_24hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability"
2098,TOX21_RT_HEPG2_FLO_32hr_viability,liver,cell line,HepG2,"Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.",TOX21_RT_HepG2_FLO_32hr_viability is one of one assay component(s) measured or calculated from theTOX21_RT_HepG2_FLO_00hr_viability. It is designed to make measurements of dead cells as detected with biofluorescent emission of fluorescent dye bound to dead cell DNA at 32 hr after exposure,TOX21_RT_HepG2_FLO_32hr_viability was designed to measure changes to biofluorescent signals produced from the key cyanine dye [CellTox Green] binding to dead cell DNA. Increases are indicative of decreased  viable cells present in the culture,"TOX21_RT_HEPG2_FLO_32hr_ctrl_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability"
2099,TOX21_RT_HEPG2_FLO_40hr_viability,liver,cell line,HepG2,"Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.",TOX21_RT_HepG2_FLO_40hr_viability is one of one assay component(s) measured or calculated from theTOX21_RT_HepG2_FLO_00hr_viability. It is designed to make measurements of dead cells as detected with biofluorescent emission of fluorescent dye bound to dead cell DNA at 40 hr after exposure,TOX21_RT_HepG2_FLO_40hr_viability was designed to measure changes to biofluorescent signals produced from the key cyanine dye [CellTox Green] binding to dead cell DNA. Increases are indicative of decreased  viable cells present in the culture,"TOX21_RT_HEPG2_FLO_40hr_ctrl_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability"
2101,TOX21_RT_HEPG2_GLO_08hr_viability,liver,cell line,HepG2,"Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.",TOX21_RT_HEPG2_GLO_08hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEPG2_GLO_00hr_viability assay. It is designed to make measurements of viable cells as detected with bioluminescence signal generated by NanoLuc luciferase catalysis of a profurimazine substrate which require intracellular reduction of the substrate in a viable cell.,TOX21_RT_HEPG2_GLO_08hr_viability was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [Profurimazine]. Changes are indicative of changes in the number of viable cells which are required for reduction of Profurimazine to a form that can be used by NanoLuc luciferase added as a detection reagent.,"TOX21_RT_HEPG2_GLO_08hr_ctrl_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability"
2102,TOX21_RT_HEPG2_GLO_16hr_viability,liver,cell line,HepG2,"Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.",TOX21_RT_HEPG2_GLO_16hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEPG2_GLO_00hr_viability assay. It is designed to make measurements of viable cells as detected with bioluminescence signal generated by NanoLuc luciferase catalysis of a profurimazine substrate which require intracellular reduction of the substrate in a viable cell.,TOX21_RT_HEPG2_GLO_16hr_viability was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [Profurimazine]. Changes are indicative of changes in the number of viable cells which are required for reduction of Profurimazine to a form that can be used by NanoLuc luciferase added as a detection reagent.,"TOX21_RT_HEPG2_GLO_16hr_ctrl_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability"
2103,TOX21_RT_HEPG2_GLO_32hr_viability,liver,cell line,HepG2,"Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.",TOX21_RT_HEPG2_GLO_32hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEPG2_GLO_00hr_viability assay. It is designed to make measurements of viable cells as detected with bioluminescence signal generated by NanoLuc luciferase catalysis of a profurimazine substrate which require intracellular reduction of the substrate in a viable cell.,TOX21_RT_HEPG2_GLO_32hr_viability was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [Profurimazine]. Changes are indicative of changes in the number of viable cells which are required for reduction of Profurimazine to a form that can be used by NanoLuc luciferase added as a detection reagent.,"TOX21_RT_HEPG2_GLO_32hr_ctrl_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability"
2105,TOX21_RT_HEPG2_GLO_40hr_viability,liver,cell line,HepG2,"Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.",TOX21_RT_HEPG2_GLO_40hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEPG2_GLO_00hr_viability assay. It is designed to make measurements of viable cells as detected with bioluminescence signal generated by NanoLuc luciferase catalysis of a profurimazine substrate which require intracellular reduction of the substrate in a viable cell.,TOX21_RT_HEPG2_GLO_40hr_viability was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [Profurimazine]. Changes are indicative of changes in the number of viable cells which are required for reduction of Profurimazine to a form that can be used by NanoLuc luciferase added as a detection reagent.,"TOX21_RT_HEPG2_GLO_40hr_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity."
2116,TOX21_ERb_BLA_Agonist_viability,kidney,cell line,HEK293T,"Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.",TOX21_ERb_BLA_Agonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.,Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.,"TOX21_ERb_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity."
2120,TOX21_ERb_BLA_Antagonist_viability,kidney,cell line,HEK293T,"Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.",TOX21_ERb_BLA_Antagonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.,Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.,"TOX21_ERb_BLA_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity."
2124,TOX21_PR_BLA_Agonist_viability,kidney,cell line,PR-UAS-bla-HEK293T,"Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.",TOX21_PR_BLA_Agonist_viability is a component of the TOX21_PR_BLA_Agonist assay. This component measures cell viability using the CellTiter-Glo Luciferase-coupled ATP quantitation.,Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.,"TOX21_PR_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity."
2128,TOX21_PR_BLA_Antagonist_viability,kidney,cell line,PR-UAS-bla-HEK293T,"Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.",TOX21_PR_BLA_Antagonist_viability is a component of the TOX21_PR_BLA_Antagonist assay. This component measures cell viability using the CellTiter-Glo Luciferase-coupled ATP quantitation.,Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.,"TOX21_PR_BLA_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity."
2213,TOX21_RT_HEPG2_GLO_24hr_viability,liver,cell line,HepG2,"Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.",TOX21_RT_HEPG2_GLO_24hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEPG2_GLO_00hr_viability assay. It is designed to make measurements of viable cells as detected with bioluminescence signal generated by NanoLuc luciferase catalysis of a profurimazine substrate which require intracellular reduction of the substrate in a viable cell.,TOX21_RT_HEPG2_GLO_24hr_viability was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [Profurimazine]. Changes are indicative of changes in the number of viable cells which are required for reduction of Profurimazine to a form that can be used by NanoLuc luciferase added as a detection reagent.,"TOX21_RT_HEPG2_GLO_24hr_ctrl_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability"
2362,TOX21_PXR_viability,liver,cell line,HepG2,"Tox21 is an interagency agreement between the NIH, NTP, FDA and EPA. NIH Chemical Genomics Center (NCGC) is the primary screening facility running ultra high-throughput screening assays across a large interagency-developed chemical library.",TOX21_PXR_viability is a component of the TOX21_PXR assay. This component measures cell viability using the CellTiter-Fluor assay system.,"The human pregnane X receptor (hPXR) regulates the expression of several drug metabolizing enzymes and induction of these proteins is a major mechanism for developing drug resistance in cancer. One such key enzyme catalyzing the drug metabolism is cytochrome P450 3A4 (CYP3A4). Changes in CYP3A4 expression affect drug metabolism, thereby reducing the therapeutic efficacy and altering toxicological response to a drug and which finally causes adverse drug interaction.","The assay component endpoint  TOX21_PXR_viability was analyzed with bidirectional fitting relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is cytotoxicity."
